Roaring Waters Capital has increased its holding in Poolbeg Pharma, lifting its voting rights to 6.55%. The investor previously held 5.74% of Poolbeg’s voting rights.
The threshold was crossed on 21 July 2026, with the company notified on the same date. The holding comprises 50,000,000 voting rights attached to shares.
No voting rights are held through financial instruments.
The disclosure signals a further increase in institutional interest in Poolbeg as the company continues to advance its POLB 001 strategy and wider intellectual property portfolio.
TR-1: Standard form for notification of major holdings
|
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i |
||||||
|
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: |
Poolbeg Pharma Plc |
|||||
|
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) |
||||||
|
Non-UK issuer |
||||||
|
2. Reason for the notification (please mark the appropriate box or boxes with an “X”) |
||||||
|
An acquisition or disposal of voting rights |
X |
|||||
|
An acquisition or disposal of financial instruments |
||||||
|
An event changing the breakdown of voting rights |
||||||
|
Other (please specify) iii: |
||||||
|
3. Details of person subject to the notification obligation iv |
||||||
|
Name |
Roaring Waters Capital |
|||||
|
City and country of registered office (if applicable) |
Dublin, Ireland |
|||||
|
4. Full name of shareholder(s) (if different from 3.) v |
||||||
|
Name |
||||||
|
City and country of registered office (if applicable) |
||||||
|
5. Date on which the threshold was crossed or reached vi: |
21/07/2026 |
|||||
|
6. Date on which issuer notified (DD/MM/YYYY): |
21/07/2026 |
|||||
|
7. Total positions of person(s) subject to the notification obligation |
||||||
|
% of voting rights attached to shares (total of 8. A) |
% of voting rights through financial instruments |
Total of both in % (8.A + 8.B) |
Total number of voting rights held in issuer (8.A + 8.B) vii |
|||
|
Resulting situation on the date on which threshold was crossed or reached |
6.55% |
0% |
6.55% |
50,000,000 |
||
|
Position of previous notification (if applicable) |
5.74% |
0% |
5.74% |
|||
|
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii |
|||||||||
|
A: Voting rights attached to shares |
|||||||||
|
Class/type of ISIN code (if possible) |
Number of voting rights ix |
% of voting rights |
|||||||
|
Direct (DTR5.1) |
Indirect (DTR5.2.1) |
Direct (DTR5.1) |
Indirect (DTR5.2.1) |
||||||
|
GB00BKPG7Z60 |
50,000,000 |
0 |
6.55% |
0% |
|||||
|
SUBTOTAL 8. A |
50,000,000 |
6.55% |
|||||||
|
|
|||||||||
|
B 1: Financial Instruments according to DTR5.3.1R (1) (a) |
|||||||||
|
Type of financial instrument |
Expiration |
Exercise/ |
Number of voting rights that may be acquired if the instrument is exercised/converted. |
% of voting rights |
|||||
|
SUBTOTAL 8. B 1 |
|||||||||
|
|
|||||||||
|
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b) |
|||||||||
|
Type of financial instrument |
Expiration |
Exercise/ |
Physical or cash Settlement xii |
Number of voting rights |
% of voting rights |
||||
|
|
SUBTOTAL 8.B.2 |
||||||||
|
|
|||||||||
|
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”) |
||||
|
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii |
||||
|
Full chain of controlled undertakings through which the voting rights and/or the |
||||
|
Name xv |
% of voting rights if it equals or is higher than the notifiable threshold |
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold |
Total of both if it equals or is higher than the notifiable threshold |
|
|
|
||||
|
10. In case of proxy voting, please identify: |
||||
|
Name of the proxy holder |
||||
|
The number and % of voting rights held |
||||
|
The date until which the voting rights will be held |
||||
|
11. Additional information xvi |
||||
|
Place of completion |
Dublin, Ireland |
|
Date of completion |
21/07/2026 |
About Poolbeg Pharma plc
Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world’s largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs.
Stay updated: Website | Sign up for RNS alerts | Presentation | X | LinkedIn
